Physician profile
Mark P Mclain
NPI 1649318486
$6,477.24
in general payments reported to CMS, 2019-2025
27 companies · $738 in 2025
The $738 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $496 · 2021: $1,376 · 2022: $1,220 · 2023: $1,102 · 2024: $818 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,657.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,250.42 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $723.46 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $702.74 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $528.26 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $479.50 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $377.57 | 2022-2025 | Auvelity, Sunosi |
| Allergan, INC. | $293.55 | 2019-2020 | |
| Lundbeck LLC | $214.20 | 2019-2024 | Rexulti |
| Tris Pharma INC | $213.30 | 2022-2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $211.75 | 2019-2023 | Spravato |
| Jazz Pharmaceuticals INC. | $199.44 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $195.13 | 2022-2024 | Austedo, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $156.09 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $154.33 | 2019-2023 | Belsomra |
| E.R. Squibb & Sons, L.L.C. | $152.63 | 2025 | Cobenfy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $139.19 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $133.13 | 2021-2023 | Caplyta |
| Neurocrine Biosciences, INC. | $115.60 | 2021-2025 | Ingrezza |
| Collegium Pharmaceutical, INC. | $52.61 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $35.42 | 2023-2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $28.78 | 2021 | |
| Arbor Pharmaceuticals, INC. | $26.41 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.16 | 2025 | |
| Alfasigma USA, INC. | $22.84 | 2020 | |
| Biogen, INC. | $17.62 | 2021 | |
| Adlon Therapeutics L.P. | $13.99 | 2020 | |
| Bausch Health US, LLC | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.